Esperion Therapeutics
(NASDAQ:ESPR)
$2.20
0.11[5.26%]
At close: May 10
$2.20
0[0.00%]
After Hours: 7:59PM EDT
Q1 2024 Earnings were released on Tue May 7th, before the market open
The most recent conference call was at 8:00 AM, 5 days ago Click to view past webcast
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

Esperion Therapeutics Stock (NASDAQ:ESPR), Quotes and News Summary

Esperion Therapeutics Stock (NASDAQ: ESPR) stock price, news, charts, stock research, profile.

Open$2.130
Close$2.190
Volume / Avg.9.426M / 6.919M
Day Range2.070 - 2.215
52 Wk Range0.700 - 3.400
Market Cap$416.681M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
51
Short Interest
9.85%
Days to Cover2.02

Recent News

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
Esperion Therapeutics reports impressive Q1 revenues of $137.74 million, up 467% Y/Y, with EPS of $0.34, beating estimates. FDA approved expanded labels for NEXLETOL & NEXLIZET. Fiscal year 2024 revenue guidance: $225-$245 million.
Vandana Singh
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday.
Avi Kapoor
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.
Avi Kapoor
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
1
1
Nov 23
2
Feb
2
Mar
1
Apr
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.2
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
ESPR
AVIR

FAQ

Q

How do I buy Esperion Therapeutics (ESPR) stock?

A

You can purchase shares of Esperion Therapeutics (NASDAQ: ESPR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Esperion Therapeutics's (ESPR) competitors?

A

Other companies in Esperion Therapeutics’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Third Harmonic Bio (NASDAQ:THRD), Theravance Biopharma (NASDAQ:TBPH), Zevra Therapeutics (NASDAQ:ZVRA) and GH Research (NASDAQ:GHRS).

Q

What is the target price for Esperion Therapeutics (ESPR) stock?

A

The latest price target for Esperion Therapeutics (NASDAQ: ESPR) was reported by HC Wainwright & Co. on Wednesday, May 8, 2024. The analyst firm set a price target for 16.00 expecting ESPR to rise to within 12 months (a possible 627.27% upside). 16 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Esperion Therapeutics (ESPR)?

A

The stock price for Esperion Therapeutics (NASDAQ: ESPR) is $2.2 last updated May 10, 2024 at 7:59 PM EDT.

Q

Does Esperion Therapeutics (ESPR) pay a dividend?

A

There are no upcoming dividends for Esperion Therapeutics.

Q

When is Esperion Therapeutics (NASDAQ:ESPR) reporting earnings?

A

Esperion Therapeutics’s Q2 earnings are confirmed for Tuesday, July 30, 2024.

Q

Is Esperion Therapeutics (ESPR) going to split?

A

There is no upcoming split for Esperion Therapeutics.

Q

What sector and industry does Esperion Therapeutics (ESPR) operate in?

A

Esperion Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch